Concepedia

1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy

Benjamin Besse, Antoine Italiano, Sophie Cousin, G. Ruiter, Enriqueta Felip, Eduardo Castañón Álvarez, Suresh S. Ramalingam, Christian Rolfo, David R. Spigel, Diana Andrew,

Annals of Oncology · 2023 · 16 citations · 0 references

Open access

Concepts

MedicineOncologyPharmacologyCancer ImmunologyImmunotherapyTumor ImmunologyBispecific AntibodiesBispecific Antibody TherapyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsLung CancerImmune Checkpoint BispecificsNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyPd-l1 BlockadeProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 Inhibitors